Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruboxistaurin

Drug Profile

Ruboxistaurin

Alternative Names: Arxxant; LY 333531

Latest Information Update: 15 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Takeda
  • Class Eye disorder therapies; Indoles; Maleimides
  • Mechanism of Action Protein kinase C beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; Heart failure

Most Recent Events

  • 09 Apr 2019 Novartis completed the spin-off of Alcon
  • 24 Jun 2018 Biomarkers information updated
  • 09 Jun 2016 Children's Hospital Medical Center and The Christ Hospital plan a phase I/II trial for Heart failure in USA (PO) (NCT02769611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top